August 29 in Basel Biozentrum, BS

Spitalstrasse 41, 4056 Basel

Jennifer Kirwan, German Cano-Sancho, Lynn Vanhaecke & Thorsten Hornemann are already confirmed as plenary speakers.

More details on this page soon!

Registration

Registration is now open on our WeezEvent website:

https://my.weezevent.com/swiss-metabolomics-society-annual-meeting-2024

Call for abstracts

Abstract submission is now open.

Important dates:
Deadline for oral presentation: June 15
Deadline for posters: August 21 (Extension for last minute submissions)

The template for abstracts is available here.


Abstract submission requires completing the form here.

Plenary speakers

JENNIFER KIRWAN

Dr Kirwan started her career as a clinical veterinarian where she became increasingly interested in translational and evidence based medicine before undertaking a PhD in metabolomics. She now heads the Berlin Institute of Health Metabolomics Platform at Charité University Hospital in Berlin, where she focuses on translational health-related metabolomics, especially on its quality management aspects. She is particularly interested in the gut-brain-heart health triad and how the microbiome influences health. She is a founding member of the German Metabolomics Society, a Central Committee member of the international Metabolomics quality assurance and quality control consortium (MQACC) and is an active member of the Precision Medicine and Pharmacogenomics working group of the International Metabolomics Society.

GERMAN CANO-SANCHO

Tenured research scientist at the French National Institute for Agricultural Research and Environment joined the LABERCA Unit (Nantes) in 2016 after a multidisciplinary training in nutrition and toxicological research. After a preliminary formation in Human Nutrition and Dietetics (2009), he focused the PhD (2013) and subsequent PostDocs (U. Rovira I Virgili SP; U California at Davis, US) to toxicological research and chemical risk assessment. His current activity involves the development and application of novel integrative workflows to identify complex exposome-disease and exposome-metabolome associations in epidemiological settings coupling high-throughput mass-spectrometry platforms and advanced statistics. He has participated in over 60 scientific publications and 30 scientific conferences. He is member of Grading of Recommendations Assessment, Development, and Evaluation (GRADE) working group on Environmental Health and the Scientific Committee of the French Foundation for the Endometriosis Research and since 2019.

LYNN VANHAECKE

Lynn Vanhaecke holds a PhD in Bioscience Engineering (2008), is Full Professor and head of the Lab of Integrative Metabolomics at Ghent University (Belgium) since 2011, and holds a 20% appointment at the Institute of Global Food Security at Queen’s University Belfast (UK) since 2018. Lynn’s major research objectives include the holistic analyses of small molecules through metabolomics and lipidomics using high-resolution mass spectrometry (including ambient ionization) in relation to the diet-microbiome-health axis . In 2023, she received an ERC Consolidator Grant to continue her work on advancing metabolomics into pediatric precision medicine (MeMoSA). She is also involved in many collaborative efforts including the first Flemish Exposome project called Flexigut, and has over 240 publications (H-index 53). Lynn is inventor in a couple of patents and holds a licensing agreement for some of the novel metabolic and lipidomic fingerprinting and metabotyping methods she developed with the company Prodigest. She is an active board member of the Nutritional genomics society, an elected board member of the Metabolomics Society, and member of the Netherlands Metabolomics Centre.

THORSTEN HORNEMANN

Dr. Thorsten Hornemann is professor for clinical chemistry at the University of Zurich where he leads the lipidomics facility. His primary interest is the sphingolipid metabolism and sphingolipid-related pathologies. His contributions encompass the development of advanced mass spectrometry based analytical methods and metabolic labeling techniques, which have been crucial for investigating the structure, function, and metabolism of sphingolipids.

His work also involves establishing novel lipid metabolites and lipid-based metabolic signatures as diagnostic and prospective biomarkers in context of metabolic diseases. One of his major achievements includes the discovery and characterization of 1-deoxySphinglipids a class of atypical and neurotoxic sphingolipids, which have been pivotal in understanding the pathogenesis of the Hereditary Sensory and Autonomic Neuropathy Type 1 (HSAN1) and the diabetic sensory neuropathy.

His work has significantly contributed to the role of sphingolipid in this condition, highlighting the importance of these lipids on nerve damage and pain perception pathways.

Program

Time Annual Meeting – Thursday, August 29th 2024 – Basel Biozentrum, BS
09:30-10:00 Welcome Coffee
10:00-10:40 Plenary 1 | Lynn Vanhaecke – Ghent University, Belgium & Queen’s University Belfast, UK
Towards point-of-care applicable metabotyping using biofluid-specific samplers directly amenable to ambient mass spectrometry
10:40-11:00 Etienne Babin – ONIRIS/LABERCA, Nantes , France
Latent-based multiblock strategies for merging chemical exposure and effect biomarkers in environmental health studies
11:00-11:20 Florence Mehl – Swiss Institute of Bioinformatics, Lausanne, Switzerland
A multiorgan map of metabolic, signaling, and inflammatory pathways that coordinately control fasting glycemia in mice
11:20-12:00 Plenary 2 | Thorsten Hornemann – University of Zurich, Switzerland
Sphingolipid metabolism in neurological diseases
12:00-12:20 Sponsors presentations 1
Waters | Shimadzu | SCIEX | Thermo Scientific
12:20-13:40 Lunch break & Poster session
13:40-14:20 Plenary 3 | Jennifer Kirwan – Charité University Hospital, Berlin, Germany
Interplay between microbiome and metabolome and its effect on health and disease – A lesson in good experimental design
14:20-14:40 Mathis Fiault – University of Geneva, Switzerland
Metabolomics and Lipidomics to investigate the synergistic effects of anti-cancer drug mixtures on kidney cancer 3D models
14:40-15:00 Kapil Dev Singh – University Children’s Hospital Basel, Switzerland
Therapeutic drug monitoring of Methotrexate by real-time breath analysis
15:00-15:15 Sponsors presentations 2
Merck | Bruker | Agilent
15:15-16:00 Coffee break & Poster session
16:00-16:20 Simon Isfort – University Hospital Bern, Switzerland
A synergistic approach, combining Mass Spectrometry Imaging (MSI) and Liquid Extraction Surface Analysis (LESA) for metabolic assessment in a Steatotic Liver Disease (SLD) model for high throughput drug screening
16:20-17:00 Plenary 4 | German Cano-Sancho – LABERCA, Nantes , France
Application of metabolomics to gain insight into the role of environmental pollutants on women’s health
17:00-17:10 Closing remarks
17:10-19:00 Apero